These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30337526)

  • 61. The cellular phenotype conditions Btk for cell survival or apoptosis signaling.
    Islam TC; Smith CI
    Immunol Rev; 2000 Dec; 178():49-63. PubMed ID: 11213806
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
    Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
    Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
    Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.
    Li T; Tsukada S; Satterthwaite A; Havlik MH; Park H; Takatsu K; Witte ON
    Immunity; 1995 May; 2(5):451-60. PubMed ID: 7538439
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.
    Satterthwaite AB; Lowell CA; Khan WN; Sideras P; Alt FW; Witte ON
    J Exp Med; 1998 Sep; 188(5):833-44. PubMed ID: 9730885
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 67. p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53.
    Hayashi S; Ozaki T; Yoshida K; Hosoda M; Todo S; Akiyama S; Nakagawara A
    Biochem Biophys Res Commun; 2006 Aug; 347(1):60-6. PubMed ID: 16815295
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
    Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
    J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
    [TBL] [Abstract][Full Text] [Related]  

  • 70. p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM.
    Stewart-Ornstein J; Lahav G
    Sci Signal; 2017 Apr; 10(476):. PubMed ID: 28442631
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.
    Kim E; Yang KS; Kohler RH; Dubach JM; Mikula H; Weissleder R
    Bioconjug Chem; 2015 Aug; 26(8):1513-8. PubMed ID: 26017814
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Palmitoylation of the Alternative Amino Terminus of the BTK-C Isoform Controls Subcellular Distribution and Signaling.
    Kokabee M; Wang X; Voorand E; Alin E; Kokabee L; Khan F; Desrosiers S; Conklin DS
    Cancer Genomics Proteomics; 2022; 19(4):415-427. PubMed ID: 35732327
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variations.
    Smith CIE; Zain R
    Eur J Haematol; 2024 Jul; 113(1):130-131. PubMed ID: 38529725
    [No Abstract]   [Full Text] [Related]  

  • 74. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
    Serda M; Malarz K; Mrozek-Wilczkiewicz A; Wojtyniak M; Musioł R; Curley SA
    Sci Rep; 2020 Jan; 10(1):260. PubMed ID: 31937861
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cell line-based assessment of BTK inhibitors.
    Krause G; Hassenrück F; Hallek M
    Br J Pharmacol; 2020 May; 177(9):2163-2165. PubMed ID: 31994176
    [No Abstract]   [Full Text] [Related]  

  • 76. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
    Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ibrutinib and
    Woyach JA
    Blood; 2018 Nov; 132(18):1869-1870. PubMed ID: 30385492
    [No Abstract]   [Full Text] [Related]  

  • 79. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.